Acceptance and Commitment Therapy for Individuals with Mild Neurocognitive Disorder and Their Care Partners
This study is testing a type of talk therapy called Acceptance and Commitment Therapy (ACT) for people with mild neurocognitive disorder (MNCD) and their care partners. ACT helps people become more flexible in their thoughts and actions. We want to see if this therapy can help reduce symptoms of depression, anxiety, and grief. To join, you must be 18 or older and able to communicate in English. For individuals with MNCD, your Mini-Mental State Exam (MMSE) score should be between 21-27. Care partners must also be 18 or older, identify as a care partner, speak English, and have an MMSE score between 28-30. The study aims to enroll 100 participants.
- Study design
- This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 100 participants, including both individuals with MNCD and their care partners.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- The study will measure changes in depression and anxiety at 6 weeks after the intervention begins.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
ACT for Individuals With MNCD and Their Care Partners
At a glance
Conditions
NCT07239609
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Texas Tech University Plaza Building
Lubbock, Texasstudy coordinator listed
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Patient Health Questionnaire-96 weeks
PHQ-9 is used to assess the presence and severity of depressive symptoms.
- Geriatric Depression Short From6 Weeks
GDS short is a brief, self-report screening tool designed to identify depressive symptoms in older adults.
- The Generalized Anxiety Disorder-76 weeks
GAD-7 is used to assess the severity of generalized anxiety symptoms
- General Anxiety Scale-106 Weeks
The GAS-10 is designed to assess the severity of general anxiety symptoms
- Pre-death grief-126 weeks
The PG-12 examines pre-death grief for persons with life limiting illnesses and their care partners.